Celyad Oncology Sa · EURONEXT:CYAD
Celyad Oncology Sa — Celyad — Investor Presentation (June 2017)
25 slides from Celyad Oncology Sa's investor presentation, June 2017
Slide 1: Corporate Presentation June 2017
Bringing Breakthrough Pioneering Therapies to Patients with Life-Threatening Diseases Corporate Presentation June 2017
Slide 2: Disclaimer
Disclaimer In addition to historical facts or statements of current condition, this presentation contains forward-looking statements, including statements about the potential safety and feasibility of CAR-T NKR-2 cell therapy, which reflect our current expectations and projections about future event
Slide 3: Celyad: Company Overview
Celyad: Company Overview Focused on the discovery and development of specialized cell-based therapies to target cancer • Novel and proprietary CAR-T platform targeting treatment of solid and hematological tumors. • Lead candidate, CAR-T NKR-2, currently enrolling in Phase 1 THINK trial in 7 indicati
Slide 4: Celyad's Robust Immuno-Oncology Pipeline
Celyad’s Robust Immuno-Oncology Pipeline 2015 2016 2017 2018 CLINICAL STAGE Autologous platform CAR-T NKR-2 SAFETY THINK - Acute Myeloid Leukemia HEMATO CANCER INDICATIONS Phase 1 Trial THINK - Multiple Myeloma THINK - Ovarian cancer THINK - Colorectal cancer THINK - Pancreatic cancer SOLID CANCER T
Slide 5: A Unique Construct Arming T-cells with a NK Receptor
A Unique Construct Arming T-cells with a NK Receptor to Target and Destroy Cancer Cells • One natural construct that capitalizes on the two main pillars of the immune system: NK cells and T-cells. • A natural co-stimulating domain: DAP 10 • Same signaling domain as other CAR-T: CD3ζ. 5
Slide 6: CAR-T NKR-2: A Novel Paradigm to CAR-T
CAR-T NKR-2: A Novel Paradigm to CAR-T The Next Frontier of Cell Therapy Increasing Deliverability and Safety Next Generation CAR-T NKR-2 Lymphodepletion No Lymphodepletion “Making Space for the Leveraging the patient A Cell Transplant Paradigm Graft” Immune System Less Controlled In Vivo Controlled
Slide 7: Significant Survival Benefit Shown in Animal Models
Significant Survival Benefit Shown in Animal Models Prolonged survival in multiple dose murine models of Ovarian, Myeloma, Lymphoma, Melanoma and Pancreatic cancers. MULTIPLE MYELOMA LYMPHOMA Reduced Pancreatic Cancer in Humanized Mice 1. Barber, A. et al., J. Immunol (2009) 183(4):2365-72 7 2. Barb
Slide 8: Multiple Modes Of Action: Targeting the Tumor Micro Environment
Multiple Modes Of Action: Targeting the Tumor Micro Environment Eliminates Tumor T Regs Recruits Macrophages to the Tumor Peritoneal cells #521- Num be r of CD4+Foxp3+ ce lls x 10^5 x 10-5 100 CCL2 CD4+ Foxp3+ cells x 10^5 80 of cells 60 Number CD4+Foxp3+ 40 Number 20 0 naïve Naive WT Control *** CH
Slide 9: Multiple Modes of Action: Disrupting Tumor Blood Supply
Multiple Modes of Action: Disrupting Tumor Blood Supply CAR-T NKR-2 targets the tumor’s neovasculature, and deprives it from the oxygen and nutrients needed to grow and survive wtNKG2D chNKG2D 9
Slide 10: Multiple Modes Of Action: Preventing Relapse
Multiple Modes Of Action: Preventing Relapse Acquired adaptive immunity for long-term recurrence protection in Multiple Myeloma (MM) model Treatment with CAR-T NKR-2 cells led Survivors were either re-challenged with to long-term survival of mice injected 5T33MM cells or with RMA cells; naive used a
Slide 11: Controlled Safety Profile: No Lymphodepletion
Controlled Safety Profile: No Lymphodepletion Sustaining a competent immune system allows for the induction of an adaptive anti-tumor immune response and avoids the potentially acute and enduring toxicities associated with chemotherapy. Cy Single Dose Control T cells NKR-2 + Cy Myeloma cancer model
Slide 12: A Single NK Cell Receptor Binding Different Ligands
A Single NK Cell Receptor Binding 8 Different Ligands NKG2D can bind to any of eight naturally occurring ligands known to be overexpressed in over 80% of solid and hematological tumors NKG2D Binding Ligands MICA MICB ULBPs 1-6 NKG2D ligands are expressed by stressed cells during infection, tumorigen
Slide 13: CAR-T NKR-2 Multiple Targets
CAR-T NKR-2 Multiple Targets Expression of at least one of NKG2D ligands: • Triple negative breast cancers : 88% • Colorectal cancers : 88% • Ovarian cancers: 68% • Bladder cancers: 78% of the primary tumors and 100% of the metastases • Pancreatic cancers: 86% • NSCLC Lung cancers: 92% (100% non-squ
Slide 14: CAR-T NKR-2, Potential Best-In-Class CAR-T Therapy
CAR-T NKR-2, Potential Best-In-Class CAR-T Therapy 80% of all cancers Impressive Preclinical Results ✓ Single receptor can recognize ✓ 100% Cancer-free survival in multiple multiple tumor antigens aggressive tumor models ✓ Target the majority of solid and ✓ Long-term adaptive immune hematological tu
Slide 15: CAR-T NKR-2 Clinical Development Plan
CAR-T NKR-2 Clinical Development Plan THINK: A multinational (EU/US), open-label, dose escalation Phase 1 study to assess the safety and clinical activity of multiple administrations of CAR-T NKR-2 CAR-T NKR-2 CAR-T NKR-2 Phase 1 Safety trial THINK Phase 1 trial • 1 administration • 3 administration
Slide 16: NKR-2 Phase I Safety Trial Successfully Completed
NKR-2 Phase I Safety Trial Successfully Completed 2015 2016 • Single administration, dose-escalation Phase I autologous CAR-T NKR-2 study in patients with Acute Myeloid Leukemia and Multiple Myeloma CAR-T NKR-2 Phase I Safety trial Dana Farber, last patient included in September 2016. ▪ 1 administra
Slide 17: THINK trial study design
THINK trial study design Phase I dose escalation segment Phase I dose expansion segment 3 3 3 Bladder Solid tumors TN Breast 3x108 1x109 3x109 Colorectal All solid tumor types Ovarian Recommended dose Pancreatic 3 3 3 Hematological 3x108 1x109 3x109 tumors AML/MDS All hematological tumor types MM Re
Slide 18: 2017 and 2018 Clinical Milestones
2017 and 2018 Clinical Milestones Q1 2017 Q2 2017 Q3 2017 Q4 2017 H1 2018 H2 2018 SOLID SOLID SOLID SOLID SOLID SOLID • Enrollment • Reporting • Reporting • Reporting • Enrollment • PFS 6- Dose 1 Dose 1 Dose 2 Dose 3 Expansion Month Data Completed Segment • Completion • Completion • Start Completed
Slide 19: 2017 and 2018 Clinical Milestones
2017 and 2018 Clinical Milestones Q1 2017 Q2 2017 Q3 2017 Q4 2017 H1 2018 H2 2018 Initiate Study Topline Data PFS 6-Month SHRINK Data Initiate Study Topline Data PFS 6-Month LINK Data Initiate Study B7H6 Initiate Study Topline Data SIBLINK 19
Slide 20: Intellectual Property and Financial Snapshot
Intellectual Property and Financial Snapshot Intellectual Property: Three patent families covering autologous products, pipeline and allogeneic platform • Allogeneic patent provides fundamental exclusivity in the field of CAR-T cells that are TCR-deficient, regardless of method used to inhibit TCR F
Slide 21: Academic Partnerships
Academic Partnerships • Institut Curie is a world class research institution focusing on cancer and immunity, and positioning translational science at the heart of its approach • March 2016: Celyad entered into a 3 year collaboration with Institut Curie • CAR-T platform developed by Celyad was inven
Slide 22: Corporate Partnerships
Corporate Partnerships • Novartis is a global healthcare company based in Switzerland that provides solutions to address • ONO is a leader in cancer-immunotherapy in Japan the evolving needs of patients worldwide with the first approved checkpoint inhibitors, OPVIDO© • May 2nd, 2017: Celyad grants t
Slide 23: Management Team
Management Team 1. Christian Homsy, CEO 2. Patrick Jeanmart, CFO 3. Jean-Pierre Latere, COO 4. Frédéric Lehmann, VP Clinical Development & Medical Affairs 5. David Gilham, VP R&D 6. Georges Rawadi, VP Business Development & IP 1 2 3 7. Philippe Dechamps, Chief Legal Officer 8. Philippe Nobels, Globa
Slide 24: Celyad ADR programme
Celyad ADR programme Celyad ADRs trade on NASDAQ Benefits of ADRs to US investors • Symbol CYAD • Clear and settle according to US standards. • Cusip 151205000 • Offer the convenience of stock quotes and dividend payments in US dollars. • Ratio 1 ORD:1 ADR • Can be purchased/sold in the same way as
Slide 25: Thank you
Thank you Contact: [email protected] BELGIUM USA Celyad SA Celyad Inc. Axis Business Park Seaport East Rue Edouard Belin, 2 2 Seaport Lane B-1435 Mont-Saint-Guibert Boston, MA. 02210 +32(0) 10 39 41 00 +1 857-990-6900 www.celyad.com